| Name | Title | Contact Details |
|---|
Real-time PCR testing for everyone Watch the video Amplifying human potential through real-time PCR It all starts with a single sample. Add chemistry, heat, and light to make the fragments of a single virus visible by amplification up to a billion fold...
S. TX Emergency Care Foundation is a Harlingen, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Needing healthcare can be hard — getting care shouldnt be. We built Luma Health because we are all patients. We believe it should be easy to see and connect with our doctor. To get the care we need, when we need it. Ours is a new vision aligned around letting systems deliver high-quality healthcare, lower the burden on staff, and provide the modern, mobile-first experience we all deserve.
Sano Intelligence, Inc. designs and develops mobile health monitoring product including a wearable sensor patch that can read and transmit blood chemistry data to smart phone. The company was founded in 2011 and is based in San Francisco, California
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.